Biotechnology
New Human Study in Nature's Scientific Reports Finds Candela's Nordlys® Non-Ablative Fractional Laser Reverses the Skin's Epigenetic Signature of Aging
First in vivo human evidence that Candela's Nordlys laser remodels DNA
methylation associated with skin aging and has a direct molecular link to skin
cancer biology
MARLBOROUGH, Mass., June 30, 2026 /PRNewswire/ -- A new peer-reviewed study
published today in Scientific Reports
2026-06-30 21:52
3593
Shantha Biologics Announces Cartridge Fill-Finish Collaboration
HYDERABAD, India, June 30, 2026 /PRNewswire/ -- Shantha Biologics today announced that it has entered into an outsourcing agreement with Novo Nordisk to provide cartridge fill-finish manufacturing services in India. The agreement with Novo Nordisk reflects Shantha Biologics' continued focus on h...
2026-06-30 21:47
3495
Bota Biosciences and BASF Introduce Bio-Identical Collagen III Powered by AI
PULNOY, France and HANGZHOU, China, June 30, 2026 /PRNewswire/ -- Bota Biosciences and BASF jointly announced the market launch of BASF's SkinNexus™ Collag3n. This 100% human-identical recombinant Collagen III fragment was developed in collaboration between the two companies and is being commerc...
2026-06-30 21:00
2589
Samsung Biologics Releases 2026 ESG Report, Highlighting Progress in Sustainable Operations and Responsible Growth
* Advanced environmental performance through renewable energy transition and enhanced carbon transparency * Strengthened sustainability management and supply chain engagement across the healthcare value chain INCHEON, South Korea, June 30, 2026 /PRNewswire/ -- Samsung Biologics (KRX: 207940.K...
2026-06-30 19:00
3598
CU Medicine Ranked World No. 2 in Gastroenterology & Hepatology
HONG KONG, June 30, 2026 /PRNewswire/ -- U.S. News & World Report has again ranked The Chinese University of Hong Kong (CUHK)'s Faculty of Medicine (CU Medicine) No. 2 globally in Gastroenterology & Hepatology, maintaining a top-three position worldwide for four consecutive editions. The Faculty ...
2026-06-30 17:43
2123
WuXi Biologics Receives Brazil ANVISA GMP Certification to Enable Global Commercial Manufacturing of Innovative Cancer Immunotherapy
WUXI, China, June 30, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that two of its manufacturing facilities in Wuxi — Drug Substance Facility 2 (MFG2) and Drug Product Facility 1 (DP1) — together ...
2026-06-30 13:49
2684
EirGenix Showcases Dual-Track Biosimilars and CDMO Strategy in U.S. Market Push at BIO 2026
SAN DIEGO, June 30, 2026 /PRNewswire/ -- At BIO 2026, EirGenix presented its comprehensive HER2-positive breast cancer biosimilar portfolio and highlighted its integrated one-stop contract development and manufacturing organization (CDMO) service platform. The company actively pursued U.S. market...
2026-06-30 13:36
2751
Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China
SAN FRANCISCO and SUZHOU, China, June 30, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metaboli...
2026-06-30 12:00
3601
Xellar Raises $50 Million Series A Financing to Build the Future of 3D Bio Intelligence
Financing will accelerate the development of human-relevant biological data infrastructure, virtual cell technologies, and next-generation drug discovery BOSTON, June 29, 2026 /PRNewswire/ -- Xellar Biosystems today announced the closing of $50 million in Series A and A+ financing to advance its ...
2026-06-30 10:06
2375
Alebund Pharmaceuticals (09637.HK) Debuts on the HKEx Main Board
Deepening Its Commitment to Kidney Disease and Accelerating Toward Becoming a Global Leader in Renal Innovation SHANGHAI, June 29, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; stock code: 09637.HK), a biopharmaceutical company focused on kidney dise...
2026-06-29 20:00
6406
Ever Supreme Launches Phase IIa Clinical Trial for CAR001, Accelerating Global Market Expansion
TAICHUNG, June 29, 2026 /PRNewswire/ -- Ever Supreme Bio Technology Co., Ltd. (TWSE: 6712) announcedon June 28 that CAR001, its proprietarily developed, allogeneic, "off-the-shelf" CAR-T cell therapy for cancer, has successfully cleared review by the Safety Monitoring Committee (SMC). Followin...
2026-06-29 16:47
2041
CHMP recommends revoking marketing authorisation for TAVNEOS® (avacopan) in the European Union
* Recommendation follows an Article 20 non-pharmacovigilance procedure * Patients currently on TAVNEOS treatment should consult their treating physician ST. GALLEN, Switzerland, June 26, 2026 /PRNewswire/ -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and CSL announced today that the...
2026-06-26 21:06
4959
Everest Medicines Announces China NMPA Acceptance of the Biologics License Application for LEROCHOL® in Adults with Hypercholesterolemia
SHANGHAI, June 26, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that China's National Medical Products...
2026-06-26 10:08
8439
NextRise 2026, Seoul Successfully Wraps Up as Asia's Leading Startup Fair Co-hosted by KITA and KDB
SEOUL, South Korea, June 26, 2026 /PRNewswire/ -- The Korea International Trade
Association (KITA) and Korea Development Bank (KDB) successfully wrapped up
NextRise 2026, Seoul, Asia's leading startup fair, at COEX in Samseong-dong,
Seoul, after a two-day run from June 18 to 19, 2026.
2026-06-26 08:00
8822
Racura Oncology Doses First Patient in Phase 1 HARNESS-1 Trial of RC220 in EGFR-Mutant Non-Small Cell Lung Cancer
Racura Oncology has dosed the first patient in the HARNESS-1 Phase 1a/b trial of RC220 in combination with osimertinib for EGFR-mutant non-small cell lung cancer. The study will assess safety, pharmacokinetics, ctDNA dynamics and early clinical activity of RC220 as a strategy to address therapeut...
2026-06-25 22:51
6023
CStone Pharmaceuticals Enters into Exclusive Commercialization Agreement with Arrotex for Sugemalimab across Australia and New Zealand
* Arrotex, the pharmaceutical commercialization platform of DBG, Australia's leading diversified healthcare group, will be responsible for the registration, market access, and commercialization of sugemalimab in Australia and New Zealand. * This partnership marks sugemalimab's fifth internati...
2026-06-25 17:44
7762
Haier Biomedical Debuts Innovative Automated Low-Carbon Cold Storage Products at Two Major Global Industry Trade Fairs
From Europe Biobank Week 2026 in Prague to Interphex Week Tokyo 2026, Haier
Biomedical continuously strengthens global life sciences market presence
through localized innovative products and profound ecosystem partnerships
QINGDAO, China, June 25, 2026 /PRNewswire/ -- Haier Biomedical
2026-06-25 17:34
8933
C-Ray Therapeutics Receives Radiopharmaceutical Manufacturing Authorization under China's MAH Framework
CHENGDU, China, June 25, 2026 /PRNewswire/ -- On June 23, 2026, C-Ray Therapeutics (Chengdu) Co., Ltd. ("C-Ray Therapeutics") completed on-site inspections conducted by a panel of experts from the Sichuan Provincial Center for Drug Evaluation and the National Defense Science and Industry Adminis...
2026-06-25 11:33
7267
ATLATL and Samsung Bioepis Launch 'Samsung Bioepis Innovation Prize C-Lab Outside' to Accelerate Early-Stage Biotech Innovation Across Asia-Pacific
Applications Open June 25 for Early-Stage Biotech Companies Developing Next-Generation Therapeutics and Platform Technologies SHANGHAI, June 25, 2026 /PRNewswire/ -- ATLATL Innovation Center ("ATLATL"), a global innovation platform for life science research and development, and Samsung Bioepis C...
2026-06-25 07:30
9115
HKeyBio Launches NHP Fast-Tox Program for Accelerating Non-GLP NHP Safety Risk Screening
The program supports early tolerability assessment, PK/TK-linked safety evaluation, immune-related risk screening, and pre-GLP dose design for biologics and immunomodulatory drug programs BOSTON and SUZHOU, China, June 24, 2026 /PRNewswire/ -- HKeyBio, a preclinical CRO focused on autoimmune and...
2026-06-24 20:36
6084
Week's Top Stories
Most Reposted
SMU School of Accountancy launches Applied AI Track for next generation of accounting and finance professionals
[Picked up by 282 media titles]
2026-10-07 11:50DayOne Files Registration Statement for Proposed Initial Public Offering
[Picked up by 279 media titles]
2026-10-06 05:28Agoda Partners with Marina Bay Sands on Bespoke Flagship Store for Experience-Led Travel
[Picked up by 277 media titles]
2026-10-08 09:50
New Asia Forum Targets US$30 Billion in Investment into the New Asia at Its Inaugural Edition in Bali
[Picked up by 274 media titles]
2026-10-09 13:21The Coffee Bean & Tea Leaf® Turns 63 and Sets a New Direction for Its Next Chapter of Growth
[Picked up by 263 media titles]
2026-10-05 13:24
Most Read
RoboParty Unveils RP1, a High-Performance Full-Stack Open-Source Humanoid Robot at IROS
2026-10-04 00:56
10447
Nuix Neo Generative AI Framework
2026-10-08 08:02
8959
Silicon Quantum Computing Named to Fast Company's 2026 Next Big Things in Tech List
2026-10-06 19:38
7891
